drugset / Trial / NCT03962998
Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability
RandomizedCrossoverOpen-labelDiagnostic
Summary
The objectives of the study are to evaluate the safety and tolerability of oral administration of MB-102, and to evaluate the use of MB-102 as a means of measuring gut permeability in normal participants (n=10) and in those with radiologic evidence of small bowel Crohn's disease (n=10).
Timeline
- Start
- 2019-10-27
- Primary completion
- 2021-10-05
- Completion
- 2021-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lactulose | Other / unclassified | 1000 mg | Oral |
| Subject | Relmapirazin | Diagnostic / imaging agent | 0.004 mmol | Oral |
| Comparator | Rhamnose | Diagnostic / imaging agent | 200 mg | Oral |